A bar graph shows US drug revenue and kickback-relevant penalties for various pharmaceutical companies from 2004-2025. GSK 2012 has the highest revenue. Teva Pharmaceuticals 2024 is also high. Kickback penalties are much lower overall.
From 2000 to 2025, US penalties for pharmaceutical manufacturer #Kickbacks averaged 2.2% of implicated drug revenue, suggesting current financial penalties may be economically tolerable for some companies.
ja.ma/4s4ujq9